Enzo Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin
Last enzo biochem, inc earnings: 12/7 04:10 pm
Check Earnings Report
US:NYSE Investor Relations: enzo.com/corporate/investor-information
NEW YORK, NY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,899,827 entitled “Antibodies Specific for Sulfation Sites of Sclerostin”. The new patent is a member of a broader U.S. and international patent family that also includes issued patents and pending patent applications for therapies including monoclonal antibodies and small synthetic peptides used to inhibit sclerostin in the treatment of bone disorders such as osteoporosis. Enzo’s patent focuses on polyclonal antibodies that bind a specific region of human sclerostin, a protein that is a negative regulator of bone growth. Sclerostin is produced in osteocytes, a type of bone cell, and is known to inhibit bone formation. The maintenance of bone over time requires a balance between the formation of new bone tissue and the breakdown and removal (resorption) of old bone tiss
[Read more]
| Impact snapshot | Event time: | ENZ | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ENZ alerts
ENZ alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENZ alerts
High impacting Enzo Biochem, Inc news events
Weekly update
A roundup of the hottest topics
ENZ
News
- Enzo Biochem, Inc. (<a href="https://www.marketbeat.com/stocks/NYSE/ENZ/price-target/">NYSE: ENZ</a>) was upgraded by analysts at TheStreet from a "d+" rating to a "c" rating.MarketBeat
- ENZO BIOCHEM TO PRESENT AT THE KEYBANC CAPITAL MARKETS' LIFE SCIENCES & MEDTECH INVESTOR FORUMGlobeNewswire
- Enzo Biochem, Inc. (ENZ) Q2 2021 Results - Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate UpdatesGlobeNewswire
- Enzo Biochem to Participate in the H.C. Wainwright Global Life Sciences ConferenceGlobeNewswire
- More
ENZ
SEC Filings
- 3/19/21 - Form 8-K
- 3/17/21 - Form SC
- 3/17/21 - Form 4
- ENZ's page on the SEC website
- More